Early-Stage Skin Cancer Detection Tool – Portable AI Diagnostic Machine Launched

Photo of author

Speclipse has launched an updated version of their proprietary AI-enabled early-stage skin cancer detection device for medical and non-medical professionals.

The medical technology specialists have updated their Spectra-Scope, an advanced scanning device used to facilitate the early detection and diagnosis of conditions such as melanoma and squamous cell carcinoma.

More details can be found here: https://www.speclipse.com

The newly updated Spectra-Scope provides medical practitioners with a swift and effective diagnostic alternative to the traditionally drawn-out procedures for identifying cancers of the skin.

Statistics show that skin cancer is one of the most prevalent forms of cancer in the United States. According to the American Academy of Dermatology, around 9,500 people nationwide are diagnosed with skin cancer every day.

By harnessing the power of laser-induced plasma spectroscopy, the Spectra-Scope can analyze biochemical information contained in skin tissue at both a molecular and atomic level. Users are able to make a fast and accurate oncological diagnosis through the device’s AI-based algorithm.

The tool offers near-instantaneous secondary verification, enabling better clinical decision-making and recommendations. Lesions identified using the Spectra-Scope have a much higher chance of positive diagnosis in later biopsies.

Scanning takes a matter of seconds to complete, saving practitioners valuable time amid their busy schedules and patient demands. Time is also of the essence in regards to effective cancer treatment, and early detection can be the difference between complete remission and a life-threatening condition.

Clinical studies have revealed the device to have 95% accuracy and 87% specificity in the identification of malignant and benign lesions, proving both its effectiveness and safety for diagnostic care.

Diagnostic results generated by the Spectra-Scope give a LIPS score which reflects the degree of malignancy of the lesion.. Previous assessments are also stored within the unit, allowing medics to quickly access relevant clinical history of lesions.

Speclipse was founded by a leading dermatologist and a group of Stanford University graduates. The team is committed to harnessing cutting-edge AI and laser technology in the treatment of skin cancer, providing advanced and cost-effective diagnostic tools.

A spokesperson says, “Over-diagnosis of skin cancer is a common first-world problem. The good news is Spectra-Scope skin cancer detection machine can help stop it.”

With the launch of its updated device, Speclipse continues to make advanced cancer diagnostics accessible to medical and non-medical professionals nationwide.

For more information, please visit https://www.speclipse.com